• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Gritstone bio Inc.

    6/24/24 5:16:01 PM ET
    $GRTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GRTS alert in real time by email
    8-K
    false 0001656634 0001656634 2024-06-17 2024-06-17

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 17, 2024

     

     

    Gritstone bio, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-38663   47-4859534
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    5959 Horton Street, Suite 300  
    Emeryville, California   94608
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 510 871-6100

     

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   GRTS   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On June 17, 2024, Gritstone bio, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 22, 2024, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 107,130,799 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 61,126,864 shares of the Company’s common stock were voted in person or by proxy for the four proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 (the “Proxy Statement”).

    Proposal No. 1 – Election of Directors

    The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors (the “Board”) to hold office until the 2027 Annual Meeting of Stockholders or until their successors are elected.

     

    Class III Director Nominees

       Votes For      Votes Withheld      Broker Non-Votes  

    Elaine Jones, Ph.D.

         35,747,618        921,821        24,457,425  

    Clare Fisher

         29,466,318        7,203,121        24,457,425  

    Proposal No. 2 – Ratification of Selection of Independent Registered Accounting Firm

    The Company’s stockholders ratified the selection, by the Audit Committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.

     

    Votes For

      

    Votes Against

      

    Abstentions

      

    Broker Non-Votes

    60,234,183    606,524    286,157    —

    Proposal No. 3 – Advisory Vote to Approve the Compensation of our Named Executive Officers

    The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

     

    Votes For

      

    Votes Against

      

    Abstentions

      

    Broker Non-Votes

    26,983,992    9,372,349    313,098    24,457,425


    Proposal No. 4 – Advisory Vote on the Preferred Frequency of Stockholder Advisory Votes to Approve the Compensation of our Named Executive Officers

    The Company’s stockholders indicated, on a non-binding advisory basis, their preference regarding the frequency of future advisory votes to approve the compensation of the Company’s named executive officers. The votes were casted as follows:

     

    Every One Year

      

    Every Two Years

      

    Every Three Years

      

    Abstained

    35,461,738    160,604    586,463    460,634

    Pursuant to the foregoing non-binding advisory votes, the stockholders approved the frequency for future advisory votes on compensation paid by the Company to its named executive officers of every one year. Consistent with the recommendation of the Company’s Board of Directors and the outcome of the stockholder vote regarding this proposal, the Company’s Board of Directors determined to hold an advisory vote once every year to approve the compensation paid by the Company to its named executive officers.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          Gritstone bio, Inc.
    Date: June 24, 2024     By:  

    /s/ Andrew Allen

         

    Andrew Allen

    President and Chief Executive Officer

    Get the next $GRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRTS

    DatePrice TargetRatingAnalyst
    10/1/2024Mkt Outperform → Mkt Perform
    JMP Securities
    2/28/2024$4.00Mkt Outperform
    JMP Securities
    3/31/2023Outperform
    Evercore ISI
    3/28/2023$8.00Buy
    B. Riley Securities
    10/31/2022$6.00Overweight
    Piper Sandler
    8/22/2022$2.00Neutral → Sell
    Goldman
    12/15/2021$15.00Neutral
    Goldman
    10/15/2021$20.00Buy
    BTIG Research
    More analyst ratings

    $GRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gritstone bio downgraded by JMP Securities

      JMP Securities downgraded Gritstone bio from Mkt Outperform to Mkt Perform

      10/1/24 7:33:47 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Gritstone bio with a new price target

      JMP Securities initiated coverage of Gritstone bio with a rating of Mkt Outperform and set a new price target of $4.00

      2/28/24 6:17:40 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Gritstone bio

      Evercore ISI initiated coverage of Gritstone bio with a rating of Outperform

      3/31/23 8:59:35 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

      SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

      11/6/24 5:34:44 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Gritstone bio Inc.

      SC 13G - Gritstone bio, Inc. (0001656634) (Subject)

      10/7/24 5:01:07 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Gritstone bio Inc.

      SC 13G/A - Gritstone bio, Inc. (0001656634) (Subject)

      7/8/24 4:32:39 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Financials

    Live finance-specific insights

    See more
    • Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

      -- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. To access by phone, dial: 1-877-407-4018Conference ID: 13746126To access by webcast, visit: https://viavid.webcasts.com/starthere.jsp?ei=1667088&tp_key=d0e680f7aa While not required, it is recommended yo

      5/2/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ

      5/11/23 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023

      EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. Live Conference Call & WebcastToll Free: 1-888-999-6281International: 1-848-280-6550Conference ID: 1754341Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1612896&tp_key=c6c637ac24 While not required, it is recommended you join five minutes prior to the

      5/3/23 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GRTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

      Voluntarily Files for Chapter 11 Restructuring Strategic Alternatives Process Continues with Interest from Parties Gritstone bio, Inc. (NASDAQ:GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternatives process. The Company is in discussions with a party to act as a stalking horse bidder or plan sponsor and intends to

      10/10/24 5:50:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

      --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell responses in GRANITE patients appears to associate with progression-free survival -- GRANITE was generally well-tolerated with no treatment discontinuations due to adverse events– -- Overa

      9/30/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad potential of Gritstone's oncology and infectious disease vaccines -- -- Cash, cash equivalents, marketable securities and restricted cash of $61.7 million as of June 30, 2024 -- EMERYVILLE, C

      8/13/24 4:05:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

      EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the appointment of Stephen Webster to its Board of Directors. A veteran finance executive in the biotechnology industry, Mr. Webster has served as an executive for several renowned companies and held key roles in raising capital, business development transactions and operations for over 30 years. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. "We are excited to welcome Stephen Webster to our Board of Directors at this important and excit

      4/29/24 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

      -- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today presented an upd

      4/8/24 7:00:00 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors

      EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company's strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (NASDAQ:GRTS). Recognized by Pharmaceutical Executive magazine as a leading business executive in the pharma and biotech industries, Dr. Hawryluk has played key roles in bridging the gap between scientific discovery and the commercial application of scientific breakthroughs. As a named invento

      12/5/22 8:30:00 AM ET
      $GRTS
      $POAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Industrial Specialties

    $GRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Allen Andrew R gifted 650,000 shares, decreasing direct ownership by 25% to 985,360 units (SEC Form 4)

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/26/24 9:25:58 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Fisher Clare

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/20/24 6:23:33 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Agarwal Shefali

      4 - Gritstone bio, Inc. (0001656634) (Issuer)

      6/20/24 6:19:11 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GRTS
    SEC Filings

    See more
    • Gritstone bio Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      10/16/24 4:06:00 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gritstone bio Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      10/10/24 8:29:59 AM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Gritstone bio Inc.

      8-K - Gritstone bio, Inc. (0001656634) (Filer)

      9/30/24 8:05:58 PM ET
      $GRTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care